All potential acute ischemic stroke patients meeting criteria for the use of IV tPA should be offered treatment. The facts are clear, and all that remains is further provider and patient education.

Use of recombinant tissue plasminogen activator (alteplase) for treatment of acute ischemic stroke outside the criteria of guidelines and licenses is not uncommon. Most important situations of off ...

A clot-dissolving tissue plasminogen activator (tPA), tenecteplase is now indicated for acute ischemic stroke on top of its ...

You may be familiar with the common signs and symptoms of a stroke: loss of vision, drooping face, weak limbs, and slurred ...

Intravenous delivered tPA is approved by the FDA for the treatment of acute ischemic stroke. The drug can make a big difference, but only if it is given within a specified time frame (up to four and a ...

For patients with mainly mild posterior circulation ischemic stroke, alteplase administered at 4.5 to 24 hours after onset results in higher frequency of functional independence.

DiaMedica Therapeutics progresses DM199 for ischemic stroke and preeclampsia, aiming to expand treatment windows. Read why ...

The effects and risks of the use of intravenous thrombolysis between 4.5 and 24 hours after the onset of a posterior circulation ischemic stroke are not well studied. In a trial conducted in China ...

Adults younger than 50 years of age had more than double the risk of having a stroke from migraine or other nontraditional stroke risk factors rather than traditional risks such as high blood pressure ...

Over the last two decades, ischemic stroke mortality rates in the U.S. have grown, with almost 3 in 10 deaths occurring at home, and increases particularly among racial minorities and rural residents.

In the Phase III EXPECTS trial, patients experiencing mostly mild posterior circulation ischemic stroke who were ineligible ...